Acquired by OPKO Health, Inc. (April 2014)
Currently available inhalers, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, are often less than effective in delivering the necessary medication.
The optimal delivery device aims for the most efficient and effective deposition of aerosol medication, accounting for drug particle/droplet size and the patient’s ability to understand and use the device.
MDIs require hand-breath coordination. DPIs are breath actuated and may require forceful inhalation. Many patients do not use these devices properly because of the complexities. With nebulizers, treatment time is relatively long, setup is cumbersome, and the apparatus is usually bulky and inconvenient.
The market needs an innovative aerosol delivery device that is convenient and easy to use; delivers medication effectively; and suits adults, children, the elderly, and the seriously ill.
Inspiro Medical is developing Inspiromatic™, a breakthrough DPI that uses advanced technology to overcome the drawbacks of current inhalers. Inspiro’s proprietary DPI is the first device to combine an active dry powder fluidization mechanism that works at low inhalation flow rates with a unique real-time feedback control and data logger indicating proper inhalation technique and follow-up.
Inspiromatic assures optimal drug delivery. Young children and the elderly will particularly benefit from the advantages of Inspiro’s dry powder inhalation.
Inspiro’s smart DPI designed for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization, an estimated 300 million people worldwide suffer from asthma, with 250,000 deaths attributed to the disease annually. COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2020.
Novel dry powder inhaler
ACQUIRED BY OPKO HEALTH, INC. (2014)
Investor: The Trendlines Group
IP: National phase
Achievements: Q2 2014 acquired by OPKO; Q4 2013 pre-marketing device; Q2 2013 completed FIM trial
Inspiro Medical acquired by OPKO
Inspiromatic™ featured in the media
Robotic external fixation system
Minimally invasive, incision-free, mesh-free repair for pelvic organ prolapse
Improved enteral feeding device
Improved treatment of bladder cancer
All-suture, "all-inside" meniscus repair system
Dual-balloon catheter for treating peripheral vascular disease
Accessible, affordable gait analysis system